Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003057367 | SCV003343830 | uncertain significance | Gastrointestinal stromal tumor | 2022-09-09 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is not expected to disrupt PDGFRA protein function. This variant has not been reported in the literature in individuals affected with PDGFRA-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces tyrosine, which is neutral and polar, with cysteine, which is neutral and slightly polar, at codon 906 of the PDGFRA protein (p.Tyr906Cys). |
Ambry Genetics | RCV004068730 | SCV005024541 | uncertain significance | Hereditary cancer-predisposing syndrome | 2023-09-27 | criteria provided, single submitter | clinical testing | The p.Y906C variant (also known as c.2717A>G), located in coding exon 19 of the PDGFRA gene, results from an A to G substitution at nucleotide position 2717. The tyrosine at codon 906 is replaced by cysteine, an amino acid with highly dissimilar properties. This amino acid position is conserved. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |